Trial Profile
A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Tibolone (Primary) ; Conjugated estrogens/medroxyprogesterone
- Indications Menopausal syndrome; Menopause; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms THEBES
- Sponsors Merck Sharp & Dohme; Organon
- 07 Oct 2009 Actual end date (Jul 2005) added as reported by ClinicalTrials.gov.
- 16 Sep 2008 Added ID, official title, endpoints, start and end dates, from clincialtrials.gov record.
- 15 Dec 2007 New trial record.